Compare Amphastar Pharmaceuticals Inc (AMPH) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Monster Beverage Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.44 (market cap $826.08M), while Monster Beverage Corp trades at $97.14 (market cap $95.25B). The key difference: Monster Beverage Corp is far larger — about 115.3× Amphastar Pharmaceuticals Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | MNST | |
|---|---|---|
Market Cap | $826.08M | $95.25B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $97.64 |
52-Week Low | $16.87 | $58.65 |
Enterprise Value | $1.22B | $93.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Monster Beverage (MNST) trades at $97.39, up 0.87% today, showing strong momentum after recent earnings beats. The stock exhibits a bullish technical trend, with moving averages supporting further upside, while oscillators are neutral. Fundamentally, the company reported robust revenue growth to $8.29 billion in 2025, with a net income margin of 23.11%, and announced a 2-for-1 stock split effective August 2026, reflecting confidence in future performance.
The outlook remains positive given consistent earnings outperformance and international expansion, but high valuation multiples like a P/E of 47.05 pose risks if growth slows. Investor sentiment is buoyed by analyst consensus favoring buys, though competitive pressures and macroeconomic factors warrant caution for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
